Agenda
October 3, 2009
Washington, DC
| RECENT ADVANCES IN THE TREATMENT OF LUNG CANCER , AND HEAD & NECK CANCER
Washington, DC – October 3, 2009 |
||
| 7:30 AM | Registration and Breakfast | |
| 8:25 AM | Welcome and Introductions | Chandra P. Belani, MD |
| Advanced Non-Small-Cell Lung Cancer ‘State of the Art’ & Antiangiogenic Therapies
Chair : Chandra P. Belani, MD |
||
| 8:30 AM | Advanced Non-Small-Cell Lung Cancer: Changes in Treatment Paradigm | Chandra P. Belani, MD |
| 8:55 AM | Integration of Bevacizumab in the Management of Non?Small-Cell Lung Cancer | Ronald Natale, MD |
| 9:20 AM | Other VEGF Targeting Agents Including Sutent, Sorafenib and Clinical Trial Designs | Ramaswamy Govindan, MD |
| 9:45 AM | Panel Discussion | |
| 10:05 AM | BREAK | |
| EGFR Directed Therapies and Emerging Novel Agents
Chair: Suresh Ramalingam, MD |
||
| 10:15 AM | Optimizing the Use of EGFR Tyrosine Kinase Inhibitors in Non?Small-Cell Lung Cancer | Suresh Ramalingam, MD |
| 10:40 PM | EGFR Monoclonal Antibodies with and without Radiation Therapy for Non?Small-Cell Lung Cancer | Ronald Natale, MD |
| 11:05 AM | Bortezemib, HDAC Inhibitors and Novel Taxanes for Non?Small-Cell Lung Cancer | Chandra P. Belani, MD |
| 11:30AM | Panel Discussion | |
| 11:50 AM | LUNCH | |
| Head & Neck Cancer and Lung Cancer Chair: Chandra P. Belani, MD |
||
| 12:50 PM | New Systemic Therapies and “State of the Art’ for Head & Neck Cancers | Corey Langer, MD |
| 1: 15 PM | Combined Modality Therapy for Lung Cancer and Head & Neck Cancer | Walter Curran, MD |
| 1:40 PM | Emerging Novel Agents for Lung Cancer and Head & Neck Cancer | Fadlo Khuri, MD |
| 2:05 PM | Panel Discussion | |
| 2:25PM | Closing Remarks & Adjourn | Chandra P. Belani, MD |